Evidence map›Paper›PMID 35288757›Full record

ArticleALTEX2022

Grouping of UVCB substances with dose-response transcriptomics data from human cell-based assays.

John S House, Fabian A Grimm, William D Klaren, Abigail Dalzell, Srikeerthana Kuchi, Shu-Dong Zhang, Klaus Lenz, Peter J Boogaard, Hans B Ketelslegers, Timothy W Gant and 2 more

Open access · goldAbstract read
In one paragraph

Article in ALTEX, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Incorporating new approach methods (NAMs) data in dose-response assessments: The future is now!Journal of toxicology and environmental health. Part B, Critical reviews · 2025
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

John S HouseBioinformatics Research Center, North Carolina State University, Raleigh, NC, USA.
Fabian A GrimmDepartment of Veterinary Integrative Biosciences, Texas A&M University, College Station, TX, USA.
William D KlarenDepartment of Veterinary Integrative Biosciences, Texas A&M University, College Station, TX, USA.
Abigail DalzellPublic Health England, Centre for Radiation, Chemical and Environmental Hazards, Harwell Science Campus, Oxon, UK.
Srikeerthana KuchiNorthern Ireland Centre for Stratified Medicine, Ulster University, L/Derry, Northern Ireland, UK.
Shu-Dong ZhangNorthern Ireland Centre for Stratified Medicine, Ulster University, L/Derry, Northern Ireland, UK.
Klaus LenzSYNCOM Forschungs und Entwicklungsberatung GmbH, Ganderkesee, Germany.
Peter J BoogaardSHELL International BV, The Hague, The Netherlands.
Hans B KetelslegersConcawe, Brussels, Belgium.
Timothy W GantPublic Health England, Centre for Radiation, Chemical and Environmental Hazards, Harwell Science Campus, Oxon, UK.
Ivan RusynDepartment of Veterinary Integrative Biosciences, Texas A&M University, College Station, TX, USA.
Fred A WrightBioinformatics Research Center, North Carolina State University, Raleigh, NC, USA.
North Carolina State University · US

Funding

Single cell, multi-parametric high throughput platform to classify endocrine disruptor potential of mixturesP42ES027704 · NIEHS · TEXAS A&M UNIVERSITY · PI Efstratios Pistikopoulos · 2017 to 2026
$21.2M
Texas A&M Center for Environmental Health Research (TiCER)P30ES029067 · NIEHS · TEXAS A&M UNIVERSITY · PI Sakhila Banu · 2019 to 2026
$13.0M
Regulatory Science in Environmental Health and ToxicologyT32ES026568 · NIEHS · TEXAS A&M UNIVERSITY · PI Weihsueh A Chiu, Natalie M Johnson · 2016 to 2026
$3.8M
NIEHS NIH HHS P30 ES029067NIEHS NIH HHS P42 ES027704NIEHS NIH HHS T32 ES026568
6 · The paper itself

Abstract

The application of in vitro biological assays as new approach methodologies (NAMs) to support grouping of UVCB (unknown or variable composition, complex reaction products, and biological materials) substances has recently been demonstrated. In addition to cell-based phenotyping as NAMs, in vitro transcriptomic profiling is used to gain deeper mechanistic understanding of biological responses to chemicals and to support grouping and read-across. However, the value of gene expression profiling for characterizing complex substances like UVCBs has not been explored. Using 141 petroleum substance extracts, we performed dose-response transcriptomic profiling in human induced pluripotent stem cell (iPSC)-derived hepatocytes, cardiomyocytes, neurons, and endothelial cells, as well as cell lines MCF7 and A375. The goal was to determine whether transcriptomic data can be used to group these UVCBs and to further characterize the molecular basis for in vitro biological responses. We found distinct transcriptional responses for petroleum substances by manufacturing class. Pathway enrichment informed interpretation of effects of substances and UVCB petroleum-class. Transcriptional activity was strongly correlated with concentration of polycyclic aromatic compounds (PAC), especially in iPSC-derived hepatocytes. Supervised analysis using transcriptomics, alone or in combination with bioactivity data collected on these same substances/cells, suggest that transcriptomics data provide useful mechanistic information, but only modest additional value for grouping. Overall, these results further demonstrate the value of NAMs for grouping of UVCBs, identify informative cell lines, and provide data that could be used for justifying selection of substances for further testing that may be required for registration.

Indexed as

Induced Pluripotent Stem CellsPetroleumBiological AssayEndothelial CellsHumansTranscriptomePetroleumdose-responseiPSC cell linesNAMspetroleumread-across

Identifiers

PMID35288757
PMCPMC9344966
OpenAlexW4221104237

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.